Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation

Science

Volumn 327, Issue 5963, 2010, Pages 348-351

  Rihel, Jason ^a   Prober, David A ^a,f   Arvanites, Anthony ^b   Lam, Kelvin ^b   Zimmerman, Steven ^a   Jang, Sumin ^a   Haggarty, Stephen J ^c,d   Kokel, David ^d   Rubin, Lee L ^b   Peterson, Randall T ^c,d,e   Schier, Alexander F ^a,b,c,e  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA BIS(4 FLUOROPHENYL)METHOXYTROPANE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; AMITRAZ; ANTIINFLAMMATORY AGENT; CETIRIZINE; CLENBUTEROL; CLONIDINE; CYCLOSPORIN; DOFETILIDE; DOPAMINE UPTAKE INHIBITOR; FEXOFENADINE; GLUCOCORTICOID; HALOFANTRINE; HALOPERIDOL; IMMUNOMODULATING AGENT; INSECTICIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL HERG; SEROTONIN UPTAKE INHIBITOR; SINAPIC ACID; SINAPIC ACID DERIVATIVE; TERFENADINE; UNCLASSIFIED DRUG; VALPROIC ACID; VERAPAMIL;

BEHAVIORAL ECOLOGY; CYPRINID; DRUG; GENE EXPRESSION; LARVA; LOCOMOTION; POTASSIUM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; HIGH THROUGHPUT SCREENING; HUMAN; LARVA; LOCOMOTION; LONG QT SYNDROME; NONHUMAN; PHENOTYPE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REST; WAKEFULNESS; ZEBRA FISH;

ALGORITHMS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BEHAVIOR, ANIMAL; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CLUSTER ANALYSIS; CYTOKINES; DRUG DISCOVERY; ETHER-A-GO-GO POTASSIUM CHANNELS; HIGH-THROUGHPUT SCREENING ASSAYS; LARVA; MOTOR ACTIVITY; POTASSIUM CHANNEL BLOCKERS; PSYCHOTROPIC DRUGS; REST; SIGNAL TRANSDUCTION; SLEEP; SMALL MOLECULE LIBRARIES; WAKEFULNESS; ZEBRAFISH; ZEBRAFISH PROTEINS;

DANIO RERIO;

EID: 74549126594     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1183090     Document Type: Article

References (21)

1. Y. Agid et al., Nat. Rev. Drug Discov. 6, 189 (2007).
2. M. N. Pangalos, L. E. Schechter, O. Hurko, Nat. Rev. Drug Discov. 6, 521 (2007).
3. See supporting material on Sdence Online.
4. R. T. Peterson, M. C. Fishman, Methods Cell Biol 76, 569 (2004).
5. R. D. Murphey, H. M. Stern, C. T. Straub, L. I. Zon, Chem. Biol. Drug Des. 68, 213 (2006).
6. T. E. North et al., Nature 447, 1007 (2007).
7. T. E. North et al., Cell 137, 736 (2009).
8. D. A. Prober, J. Rihel, A. A. Onah, R. J. Sung, A. F. Schier, J. Neurosci, 26, 13400 (2006).
9. P. G. Jorens, E. Zandijk, L. Belmans, P. J. Schepens, L. L. Bossaert, Hum. Exp. Toxicol. 16, 600 (1997).
10. B. H. Yoon et al., Life Sci. 81, 234 (2007).
11. A. Matteucci et al., Exp. Brain Res. 167, 641 (2005).
12. M. B. Wie et al., Neurosci. Lett. 225, 93 (1997).
13. K. A. Jacobson et al., Neuropharmacology 36, 1157 (1997).
14. L. Imeri, M. R. Opp, Nat. Rev. Neurosci, 10, 199 (2009).
15. U. Langheinrich, G. Vacun, T. Wagner, Toxicol. Appl. Pharmacol. 193, 370 (2003).
16. E. Raschi, V. Vasina, E. Poluzzi, F. De Ponti, Pharmacol. Res. 57, 181 (2008).
17. C. L. Douglas et al., BMC Biol. 5, 42 (2007).
18. C. Cirelli et al., Nature 434, 1087 (2005).
19. C. J. Fowler, T. J. Mantle, K. F. Tipton, Biochem. Pharmacol. 31, 3555 (1982).
20. E. Bar-Meir et al., Crit. Rev. Toxicol. 37, 279 (2007).
21. We thank J. Dowling, D. Milan, and G. Vanderlaan for suggestions and reagents and D. Schoppik, G. Uhl, and I. Woods for critical reading of the manuscript. Supported by a Bristol-Myers Squibb postdoctoral fellowship of the Life Sciences Research Foundation (J.R.), a Helen Hay Whitney Foundation postdoctoral fellowship (D.A.P.), a NIH Pathway to Independence grant (D.A.P.), the Stanley Medical Research Institute (S.J.H.), the Harvard Stem Cell Institute (L.L.R.), NIH grants MH086867 and MH085205 (R.T.P.), and grants from NIH and the Mcknight Endowment Fund for Neuroscience (A.F.S.). L.L.R. is a founder of iPierian Inc., a biotechnology company, and is a member of its scientific advisory board.